跳至主要内容
临床试验/NCT01518257
NCT01518257已完成1 期

Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthritis Knee Pain

Allergan0 个研究点目标入组 121 人开始时间: 2012年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Allergan
入组人数
121
主要终点
Change From Baseline in the Average Daily Worst Pain Intensity Score at Week 4

研究概览

简要总结

This study will evaluate the efficacy and safety of a single intra-articular (IA) injection of botulinum toxin Type A compared with placebo as treatment for osteoarthritis (OA) knee pain.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Painful osteoarthritis in the study knee
  • Able to walk without assistive walking devices, able to perform usual daily activities, and agree to maintain similar activity level throughout the study

排除标准

  • Chronic pain conditions other than knee osteoarthritis
  • Presence of bursitis, meniscus tear, ligament tear, or significant injury to the study knee within 1 year
  • Surgery to the study knee within 24 weeks
  • Treatment with hyaluronic acid in the study knee within 24 weeks
  • Treatment with corticosteroids in the study knee within 12 weeks
  • Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis
  • Previous treatment with botulinum toxin of any serotype for any reason

研究组 & 干预措施

botulinum toxin Type A

Experimental

A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.

干预措施: botulinum toxin Type A (Biological)

Placebo

Placebo Comparator

A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.

干预措施: Normal Saline (Drug)

结局指标

主要结局

Change From Baseline in the Average Daily Worst Pain Intensity Score at Week 4

时间窗: Baseline, Week 4

The patient rated their daily worst pain intensity in the study knee using an 11-point scale where: 0=no pain to 10=worst pain possible. The daily scores over the previous 14-day period were averaged. A negative change from Baseline indicated improvement.

Change From Baseline in the Average Daily Worst Pain Intensity Score at Week 8

时间窗: Baseline, Week 8

The patient rated their daily worst pain intensity in the study knee using an 11-point scale where: 0=no pain to 10=worst pain possible. The daily scores over the previous 14-day period were averaged. A negative change from Baseline indicated improvement.

Change From Baseline in the Average Daily Worst Pain Intensity Score at Week 12

时间窗: Baseline, Week 12

The patient rated their daily worst pain intensity in the study knee using an 11-point scale where: 0=no pain to 10=worst pain possible. The daily scores over the previous 14-day period were averaged. A negative change from Baseline indicated improvement.

次要结局

  • Change From Baseline in Western Ontario and McMaster Universities Arthritis (WOMAC™) Total Index Score(Baseline, Week 8)
  • Change From Baseline in WOMAC Pain Score(Baseline, Week 8)
  • Change From Baseline in WOMAC Physical Function Score(Baseline, Week 8)
  • Patient Global Impression of Change Score(Week 8)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验